Study guide

3.3 Venous Thromboembolism & Vascular Emergencies

Clinical Officers Council Pre-Internship Examination Kenya

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Overview & Exam Strategy

1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy

2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)

2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections

3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)

3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies

4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)

4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology

5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)

5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis

6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)

6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions

7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)

7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening

8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)

8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care

9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)

9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures

10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)

10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis

11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)

11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy

12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)

12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies

13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)

13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria

14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)

14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services

15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)

15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases

16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)

16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring

17 Chapter 17: Health Systems Management — Leadership, Policy & Financing

17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal

18 Chapter 18: Health Commodities, Information & Quality Management

18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety

19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility

19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance

3.3 Venous Thromboembolism & Vascular Emergencies

Key Takeaways Explain This Topic AI

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) represent a single disease spectrum governed by Virchow's triad (venous stasis, endothelial injury, hypercoagulability); risk assessment must be structured using validated Wells criteria.

In low-probability Wells score patients, a high-sensitivity D-dimer safely excludes venous thromboembolism without advanced imaging; in high-probability patients (Wells >= 2 for DVT, Wells > 4 for PE), D-dimer is bypassed and immediate definitive imaging (Compression Duplex Ultrasound or CT Pulmonary Angiography) is mandatory.

Massive (high-risk) Pulmonary Embolism is defined by sustained systemic hypotension (systolic BP < 90 mmHg) or cardiogenic shock from acute right ventricular failure; it mandates emergent systemic thrombolysis (e.g., Alteplase 100 mg IV) and cautious hemodynamic support.

Warfarin initiation mandates an absolute minimum of 5 days of concurrent therapeutic parenteral anticoagulation (LMWH or UFH) until the INR reaches 2.0 to 3.0 on two consecutive days, preventing paradoxical prothrombotic necrosis triggered by early protein C depletion.

Direct Oral Anticoagulants (DOACs) such as Rivaroxaban and Apixaban are preferred first-line agents for non-cancer VTE, offering fixed oral dosing without routine coagulation monitoring or requirement for initial heparin bridging.

Last updated: September 2026

3.3 Venous Thromboembolism & Vascular Emergencies

Core Clinical Rule: Whenever initiating Warfarin for acute venous thromboembolism, always co-administer therapeutic parenteral anticoagulation (LMWH or UFH) for an absolute minimum of 5 days AND until the INR is between 2.0 and 3.0 for at least 2 consecutive days . Premature cessation of heparin unmasks a paradoxical hypercoagulable state caused by rapid depletion of natural anticoagulant Protein C while factor II persists, precipitating catastrophic thrombotic extension or skin necrosis.

Venous Thromboembolism (VTE), comprising Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), represents one of the most preventable causes of inpatient morbidity and mortality across Kenyan hospitals. In surgical, obstetric, and acute medical wards, failure to stratify venous thromboembolic risk and promptly initiate prophylactic or therapeutic anticoagulation leads to devastating clinical outcomes.

1. Pathophysiology and Virchow's Triad

Thrombus formation within the venous circulation is governed by Virchow's Triad , described in 1856 and still foundational to vascular medicine: [VIRCHOW'S TRIAD]

  • |
  • +-------------------------+-------------------------+
  • | | |
  • [Endothelial Injury] [Venous Stasis] [Hypercoagulability]
  • | | |
  • Major orthopedic surgery • Prolonged bed rest • Active malignancy
  • (total hip/knee) • Post-operative state • Pregnancy & puerperium
  • Major pelvic/abdominal • Paralysis / stroke (highest in first 6 wks)
  • trauma • Long-distance travel • Combined oral contraceptives
  • Central venous catheter • Congestive HF • Antiphospholipid syndrome
  • Direct vascular shear • Severe obesity • Factor V Leiden mutation

In the Kenyan clinical context, high-risk populations include women in the puerperium (especially following Cesarean Section), patients with advanced pelvic malignancies (cervical and prostate carcinomas), patients immobilized with skeletal traction for femur fractures, and patients with severe systemic infections (advanced HIV disease and sepsis).

  • 2. Deep Vein Thrombosis (DVT)
  • Clinical Presentation and Physical Signs

DVT occurs predominantly in the deep veins of the lower extremities (popliteal, femoral, and iliac veins). Symptoms and physical examination findings include:

Unilateral limb pain and tenderness , typically worsening on weight-bearing.

Unilateral leg swelling: A difference in calf circumference >= 3 cm measured 10 cm below the tibial tuberosity is a highly sensitive physical indicator of unilateral edema.

Erythema, warmth, and dilated superficial collateral veins (non-varicose).

Homans' Sign: Pain in the calf on forced passive dorsiflexion of the ankle. Clinical Caveat: Homans' sign is neither sensitive nor specific, and forceful manipulation carries a theoretical risk of dislodging the thrombus. It should not be relied upon for clinical diagnosis.

Severe Limb-Threatening Complications

Phlegmasia Alba Dolens ('Milk Leg'): Extensive deep venous thrombosis without collateral occlusion. The leg is pale, cool, and massively swollen, but arterial pulses remain palpable.

Phlegmasia Cerulea Dolens: Massive, near-total thrombosis of all deep and collateral venous drainage pathways of the iliofemoral system. Characterized by severe cyanosis (violaceous discoloration), excruciating pain, massive woody edema, arterial spasm, sensory motor deficits, and bullae formation. Without emergent venous decompression (catheter-directed thrombolysis or surgical thrombectomy), it rapidly progresses to venous gangrene and requires limb amputation.

Wells Score for DVT and Diagnostic Algorithm +-----------------------------------------------------------------------------------+

  • | WELLS CLINICAL SCORE FOR DVT |
  • +-----------------------------------------------------------------------------------+
  • | Clinical Feature | Points |
  • +-----------------------------------------------------------------------+-----------+
  • | Active cancer (treatment ongoing, within past 6 months, or palliative)| +1.0 |
  • | Paralysis, paresis, or recent plaster immobilization of lower limb | +1.0 |
  • | Recently bedridden >= 3 days or major surgery within 12 weeks | +1.0 |
  • | Localized tenderness along the distribution of the deep venous system | +1.0 |
  • | Entire leg swollen | +1.0 |
  • | Calf swelling >= 3 cm compared to the asymptomatic leg (10cm below TT)| +1.0 |
  • | Pitting edema confined to the symptomatic leg | +1.0 |
  • | Collateral superficial veins (non-varicose) | +1.0 |
  • | Previously documented DVT | +1.0 |
  • | Alternative diagnosis at least as likely as DVT (e.g. cellulitis, cyst)| -2.0 |

+-----------------------------------------------------------------------------------+ [Suspected Lower Extremity DVT]

  • |
  • [Calculate Wells Score]
  • |
  • +--------------------+--------------------+
  • | |
  • [Wells < 2: DVT Unlikely] [Wells >= 2: DVT Likely]
  • | |
  • [Perform D-Dimer] [Compression Duplex]
  • | [Ultrasound]
  • +---------+---------+ |
  • | | +---------+---------+
  • [Negative] [Positive] | |
  • (< 500 mcg/L) (>= 500 mcg/L) [Positive] [Negative]
  • | | | |
  • DVT Excluded [Compression Duplex] Initiate Full Repeat scan in
  • No treatment [Ultrasound] Anticoagulation 1 week or D-dimer

Compression Duplex Ultrasonography: The non-invasive imaging modality of choice. The pathognomonic diagnostic criterion is failure of the vein lumen to completely compress under direct probe pressure in B-mode imaging, accompanied by absence of Doppler flow signals.

3. Pulmonary Embolism (PE)

Pulmonary Embolism arises when a venous thrombus (typically originating in the iliofemoral venous system) detaches and travels through the inferior vena cava, right atrium, and right ventricle to impact within the pulmonary arterial tree.

  • Pathophysiology of Right Ventricular Failure and Shock [Pulmonary Artery Thrombus Occlusion]
  • |
  • v
  • [Sudden Spike in Pulmonary Vascular Resistance (PVR)]
  • |
  • v
  • [Acute Right Ventricular (RV) Pressure Overload & Dilation]
  • |
  • v
  • [Shift of Interventricular Septum Leftward (Septal Bowing)]
  • |
  • v
  • [Impaired Left Ventricular Diastolic Filling & Reduced Stroke Volume]
  • |
  • v
  • [Systemic Hypotension, Reduced Coronary Perfusion, RV Ischemia & Shock]
  • Clinical Presentation and Wells Criteria for PE

Symptoms: Sudden-onset dyspnea (most common symptom, > 80%), pleuritic chest pain (due to peripheral infarction of visceral pleura), cough, hemoptysis , and syncope (indicates transient massive RV outflow tract obstruction and heralds life-threatening instability).

Signs: Tachypnea (RR > 20/min; most common physical sign), tachycardia (HR > 100 bpm), loud pulmonary component of the second heart sound ( P 2 P_2 P 2 ​ ), elevated JVP, and fever ( < 38.5 ∘ C < 38.5^\circ\text{C} < 38. 5 ∘ C ). +-----------------------------------------------------------------------------------+

  • | WELLS CLINICAL SCORE FOR PE |
  • +-----------------------------------------------------------------------------------+
  • | Clinical Feature | Points |
  • +-----------------------------------------------------------------------+-----------+
  • | Clinical signs and symptoms of DVT (minimum leg swelling/pain on palpation) | +3.0 |
  • | An alternative diagnosis is less likely than PE | +3.0 |
  • | Heart rate > 100 beats per minute | +1.5 |
  • | Immobilization (>= 3 days) or surgery within previous 4 weeks | +1.5 |
  • | Previous documented DVT or PE | +1.5 |
  • | Hemoptysis | +1.0 |
  • | Active malignancy (treated within 6 months or palliative) | +1.0 |
  • +-----------------------------------------------------------------------------------+
  • | Wells <= 4.0: PE Unlikely -> High-Sensitivity D-Dimer (rules out PE if negative) |
  • | Wells > 4.0: PE Likely -> Immediate CT Pulmonary Angiography (CTPA) |
  • +-----------------------------------------------------------------------------------+
  • Diagnostic Investigations

Computed Tomography Pulmonary Angiography (CTPA): The gold-standard definitive imaging test . Demonstrates sharp intraluminal filling defects surrounded by iodinated contrast. Contraindicated in severe renal failure ( e G F R < 30 mL/min eGFR < 30\text{ mL/min} e GFR < 30 mL/min ) or severe contrast allergy.

Ventilation-Perfusion (V/Q) Lung Scintigraphy: Diagnostic test of choice when CTPA is contraindicated or unavailable, or in pregnancy with normal chest radiography. Demonstrates wedge-shaped areas of mismatched ventilation without perfusion .

12-Lead Electrocardiogram (ECG):

Sinus tachycardia is the single most common ECG abnormality.

Classic S 1 Q 3 T 3 S_1Q_3T_3 S 1 ​ Q 3 ​ T 3 ​ Pattern (McGinn-White Sign): Deep S-wave in lead I, pathological Q-wave in lead III, and inverted T-wave in lead III. Indicates acute right ventricular strain; classic for exams but present in < 20 % < 20\% < 20% of cases.

T-wave inversions in right precordial leads ( V 1 − V 4 V_1-V_4 V 1 ​ − V 4 ​ ) and new incomplete or complete Right Bundle Branch Block (RBBB).

Arterial Blood Gas (ABG): Demonstrates hypoxemia , hypocapnia (due to tachypnea-induced hyperventilation), respiratory alkalosis , and an elevated alveolar-arterial ( A − a A-a A − a ) oxygen gradient.

Severity Classification and Risk Stratification

Classification Hemodynamic Parameters RV Dysfunction / Biomarkers Initial Management Strategy

Massive (High Risk) Sustained hypotension (SBP < 90 mmHg for > 15 min, or requiring inotropes) or shock Severe RV dysfunction on echo/CT; elevated Troponin or BNP Emergency Resuscitation + Systemic Thrombolysis (Alteplase)

Submassive (Intermediate Risk) Hemodynamically stable (SBP >= 90 mmHg) RV strain on echo/CT AND/OR elevated Troponin I/T or BNP Inpatient HDU admission; therapeutic LMWH or DOAC; close monitoring

Low Risk Hemodynamically stable Normal RV function on echo/CT; normal cardiac biomarkers Therapeutic LMWH or DOAC; early discharge consideration

  • 4. Anticoagulation Pharmacotherapy & Protocols
  • Acute Parenteral Anticoagulants

Low Molecular Weight Heparin (LMWH - Enoxaparin):

Dosing: 1 mg/kg subcutaneous 12-hourly , OR 1.5 mg/kg subcutaneous once daily .

Advantages: Highly predictable bioavailability and renal clearance; routine laboratory monitoring of anti-Xa activity is unnecessary in uncomplicated patients. Associated with lower incidence of Heparin-Induced Thrombocytopenia (HIT) compared to UFH.

Renal Impairment Modification: If C r C l < 30 mL/min CrCl < 30\text{ mL/min} C r Cl < 30 mL/min , reduce dose to 1 mg/kg SC once daily , or transition to Unfractionated Heparin.

Unfractionated Heparin (UFH):

Dosing: Weight-based protocol: 80 units/kg IV bolus , followed by continuous infusion at 18 units/kg/hour .

Laboratory Monitoring: Monitor the activated Partial Thromboplastin Time (aPTT) every 6 hours, adjusting the infusion rate to maintain a therapeutic range of 1.5 to 2.5 times the control (typically 60 to 85 seconds).

Clinical Placement: Preferred agent in severe renal failure ( C r C l < 30 mL/min CrCl < 30\text{ mL/min} C r Cl < 30 mL/min ) , in patients with massive PE with shock , and in patients anticipated to require emergent surgical embolectomy due to its short half-life (60–90 minutes) and rapid reversibility.

Reversal Agent: Protamine Sulfate (1 mg reverses 100 units of UFH; max single dose 50 mg IV slow push).

Heparin-Induced Thrombocytopenia (HIT):

Life-threatening immune-mediated complication triggered by IgG antibodies directed against platelet factor 4 (PF4)-heparin complexes. Leads to platelet activation, consumptive thrombocytopenia (drop in platelet count by > 50% between days 5 and 10 of therapy), and catastrophic arterial and venous thrombosis ('white clot syndrome').

Management: Immediately discontinue all heparin products (including flushes). Switch to a non-heparin parenteral anticoagulant (e.g., Fondaparinux, Argatroban). Never initiate warfarin until platelet count has fully normalized.

Direct Oral Anticoagulants (DOACs)

Modern clinical guidelines recommend DOACs as first-line therapy over Warfarin for non-cancer VTE due to fixed oral dosing, lack of routine INR monitoring, and a significantly reduced incidence of fatal intracranial hemorrhage:

Rivaroxaban (Direct Factor Xa Inhibitor): 15 mg PO twice daily taken with food for 21 days , followed by 20 mg PO once daily taken with food . Key Advantage: No initial parenteral heparin lead-in required.

Apixaban (Direct Factor Xa Inhibitor): 10 mg PO twice daily for 7 days , followed by 5 mg PO twice daily . Key Advantage: No initial parenteral heparin lead-in required.

Dabigatran (Direct Thrombin Inhibitor): 150 mg PO twice daily, initiated only after at least 5 days of initial parenteral anticoagulation.

  • Warfarin and the Mandatory Bridging Protocol Day 1 Day 2 Day 3 Day 4 Day 5 Day 6+
  • =================================================================================
  • [Therapeutic LMWH or UFH Infusion (Continued)] ------------------> | (Discontinue
  • | ONLY IF
  • [Warfarin 5 mg PO Daily Started Concurrently] -------------------> | INR >= 2.0
  • | for 2 days)
  • =================================================================================

*Pharmacological Hazard: Protein C has a 6-hr half-life and plummets on Days 1-2.

Prothrombin (Factor II) has a 60-hr half-life and remains fully active.

Without heparin bridging, uninhibited Factor II + depleted Protein C =

PARADOXICAL THROMBOSIS & WARFARIN SKIN NECROSIS!

Target Therapeutic Range: Warfarin inhibits Vitamin K Epoxide Reductase ( V K O R C 1 VKORC1 V K ORC 1 ). The target International Normalized Ratio (INR) for VTE is 2.0 to 3.0 (therapeutic target 2.5).

Reversal of Warfarin Toxicity:

Major/Life-Threatening Bleeding: Stop warfarin, administer Vitamin K (Phytomenadione) 5–10 mg slow IV push over 20 minutes, combined with 4-Factor Prothrombin Complex Concentrate (PCC) (25–50 units/kg IV). If PCC is unavailable in resource-constrained facilities, infuse Fresh Frozen Plasma (FFP) (15 mL/kg).

Duration of Anticoagulant Therapy

Provoked VTE (Transient/Reversible Risk Factor e.g., major surgery, fracture, estrogen therapy): 3 months of full-dose therapeutic anticoagulation.

Unprovoked (Idiopathic) VTE or Recurrent VTE: Extended / Indefinite anticoagulation (minimum 6 months followed by ongoing risk-benefit review).

Cancer-Associated Thrombosis (CAT): LMWH (Enoxaparin) or approved DOACs (Apixaban, Rivaroxaban) for at least 6 months , continued indefinitely while active cancer or systemic chemotherapy persists.

Emergency Management of Massive (High-Risk) PE

Hemodynamic Resuscitation: Place patient on high-flow oxygen. Infuse a cautious, conservative crystalloid fluid challenge ( <= 500 mL normal saline ). Warning: Aggressive volume resuscitation overdistends the failing right ventricle, worsens septal bowing, and precipitates immediate cardiovascular collapse. Initiate vasopressor support with Norepinephrine (0.05–0.5 mcg/kg/min) to restore systemic perfusion pressure and right coronary artery blood flow.

Systemic Thrombolysis (Fibrinolytic Therapy):

Agent & Regimen: Recombinant tissue Plasminogen Activator (Alteplase / tPA) 100 mg IV infusion over 2 hours , OR an accelerated infusion of 0.6 mg/kg over 15 minutes (max 50 mg) in cardiac arrest. Alteplase converts plasminogen to plasmin, degrading fibrin clots, reducing RV afterload, and restoring hemodynamic stability.

Alternative in Resource-Limited Settings: Streptokinase 250,000 IU loading dose IV over 30 minutes, followed by 100,000 IU/hour infusion for 12 to 24 hours.

Inferior Vena Cava (IVC) Filters: Indicated strictly when there is an absolute contraindication to therapeutic anticoagulation (e.g., active major internal bleeding, recent intracranial hemorrhage) or documented recurrent PE despite proven therapeutic anticoagulation .